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Circular dichroismLRRK2 is a 250 kDa multidomain protein, mutations in which cause familial Parkinson's disease. Previously,
we have demonstrated that the R1441C mutation in the ROC domain decreases GTPase activity. Here we
show that the R1441C alters the folding properties of the ROC domain, lowering its thermodynamic stability.
Similar to small GTPases, binding of different guanosine nucleotides alters the stability of the ROC domain,
suggesting that there is an alteration in conformation dependent on GDP or GTP occupying the active site.
GTP/GDP bound state also alters the self-interaction of the ROC domain, accentuating the impact of the
R1441C mutation on this property. These data suggest a mechanism whereby the R1441C mutation can
reduce the GTPase activity of LRRK2, and highlights the possibility of targeting the stability of the ROC
domain as a therapeutic avenue in LRRK2 disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Leucine rich repeat kinase 2 (LRRK2) is a member of the ROCO
family of proteins, deﬁned by the presence of a ROC (Ras of complex
proteins) domain followed by a domain of unknown function termed
C-terminal of ROC, or COR [1]. In LRRK2, these domains are ﬂanked
towards the C- and N-termini respectively by leucine rich repeat
(LRR) and kinase domains that give this protein its name, along with a
number of protein/protein interaction domains [2]. The function of
LRRK2 is unknown, but several mutations in this protein have been
shown to cause autosomal dominant Parkinson's disease (PD) [3,4].
Overall, mutations in LRRK2 are themost common genetic cause of PD
[5,6]. Due to their recent description and large size, very little is
known about the biochemistry and function of the ROCO proteins.
Studies focusing on the enzymatic activities of LRRK1 and LRRK2 have
suggested that the GTPase activity of these proteins regulates their
kinase activity, in a manner analogous to the interaction of small; CD, circular dichroism; GDP,
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ll rights reserved.GTPases and associated kinases such as Ras and Raf [7-9]. Studies of
mutations linked to Parkinson's disease have shown that the kinase
activity of LRRK2 is required for cytotoxicity associated with
mutations [10-14]. However, while mutations in the kinase domain
have a modest activating effect on kinase activity, mutations in the
ROC domain of LRRK2 have not consistently been shown to affect
kinase activity [15]. These same ROC domain mutations consistently
disrupt the GTPase activity of the protein, which might lead to altered
regulation of kinase activity, although the mechanistic basis for this is
unclear [16-19]. These studies highlight the role of the enzymatic
activities of LRRK2 in the disease process, but the exact functional and
spatial relationship between these two domains is unknown.
We have previously demonstrated that the R1441C mutation
decreases the GTPase activity of LRRK2 in the context of the full-
length protein [16]. The crystal structure of LRRK2 ROC domain
showed that the R1441 residue is distal to the active site of the
protein and revealed that the R1441 residue sits at the interface
between two constituent monomers in a dimeric structure [19]. This
observation suggests that mutations at this residue could destabilize
the interaction between the monomers, which might be the
mechanism of enzymatic dysfunction. Consistent with this obser-
vation, we demonstrated that the ROC domain containing the
R1441C mutation has a decreased ability to precipitate the full-
length protein from cell lysates. However, the recent report of the
crystal structure of a fragment of a ROCO protein from the
prokaryote Chlorobium Tepidium consisting of the ROC and COR
domains (the C. Tepidium ROCO protein does not contain a kinase
1195Y. Li et al. / Biochimica et Biophysica Acta 1792 (2009) 1194–1197domain) suggested that the role of R1441 is mainly inter-domain
association. This alternative model implied that mutations at LRRK2
R1441 should not perturb the structure of the ROC GTPase domain
itself, and instead acts to disrupt its interaction with the COR
domain [20]. To further investigate the mechanism whereby the
R1441C mutation disrupts ROC/ROC interactions and how it
decreases the GTPase activity of LRRK2, we have used a variety of
biophysical approaches including circular dichroism spectropolari-
metry and differential scanning ﬂuorimetry to assess the folding
characteristics of the ROC domain and to test whether the R1441C
mutation alters these characteristics.
2. Materials and methods
2.1. Protein production and puriﬁcation
The ROC domain of LRRK2 was expressed and puriﬁed as
previously reported [21]. Where only the wild type protein was
used, the 6× polyhistidine tag was removed as described [21]. The
R1441C mutant protein was expressed and puriﬁed as a 6xHis tagged
fusion and was used to compare with the 6xHis tagged WT ROC
protein. Attempts to remove the 6xhis tag from the mutant protein
failed due to the drastically decreased stability of the protein (data not
shown). Attempts to purify a GTP binding dead (K1347A) mutant
form of the protein in a soluble form were also unsuccessful (data not
shown).
2.2. Circular dichroism
Spectra were recorded with a Jasco J715 spectropolarimeter and
measured at a protein concentration of 1 mg ml−1 with a 0.01 cm
path length. The spectra are an average of 50 scans at 25 °C, with
background molecular ellipticity due to the buffer subtracted, in the
presence of 4 mM GDP. Analysis of protein stability was carried out
with a protein concentration of 0.1 mg ml−1 and a 5 mm path
length (measurements were taken over a 10 nm bandwidth
centered around 220 nm). Unfolding was carried out by melting
over a temperature gradient from 25 °C to 85 °C, ramping by 1°
every minute. The ellipticity signal (h) was converted to proportionFig. 1. (A) CD analysis of the wild type ROC domain, displaying absorption spectra typical o
absence of ligand using CD (B) and DSF (C) to follow loss of structure (D) DSFmeasurement oof molecules in the native state αN, according to the relationship
αN=(θ−θU)/(θN−θU), where θU and θN are the ellipticity signals
for the unfolded and native states, respectively. Data were ﬁtted to
the Van't Hoff function and the mid-point of thermal denaturation
(Tm) deﬁned as DH/DS.
2.3. Differential scanning ﬂuorimetry
Thermal denaturation curves were also obtained using a Bio-Rad
iCycler Single Wavelength Real-Time PCR Detection System (Bio-Rad
Laboratories, Hercules, CA) and SYPRO Orange ﬂuorescence dye
(Invitrogen, Carlsbad, CA) with an excitation and emission wave-
length of 490 nm and 520 nm, respectively. The 6xHis tagged ROC
domain proteins (WT and R1441C) were subjected to a thermal
gradient of 0.5 °C increments from 23 °C to 75 °C. The 50 μl reaction
consisted of 0.25 mg/ml protein in 100 mM HEPES, 150 mM NaCl,
20 mM MgCl2, pH 7.5 and a 2 × SYPRO Orange ﬁnal concentration
diluted from concentrated stock. Guanine nucleotide ligands (GDP,
GTP and GppNP) were added at a ﬁnal concentration of 2 mM
accordingly. All experiments were performed with ﬁve replicates. The
Tm for each sample was calculated using the ﬁrst derivative of the
normalized ﬂuorescence.
2.4. Pulldown assay
Puriﬁed WT and R1441C 6xhis tagged ROC proteins were mixed
with excess amounts of puriﬁed WT v5-tagged ROC. The protein
mixtures were then incubated with Ni-NTA superﬂow resin for
1 hour at 4 °C, in buffer A containing 20 mM Tris, 500 mM NaCl,
20 mM Imidazole, 20 mM MgCl2, 10% Glycerol, pH 8.0. Different
guanine nucleotide ligands (GDP, GTP and GppNP) were added to a
ﬁnal concentration of 2 mM accordingly. After extensive wash with
buffer A, proteins were eluted from Ni-NTA. Co-puriﬁed proteins
were analyzed by SDS-PAGE and western blotting with biotinylated
anti-V5 antibody (1:10000). Streptavidin conjugated HRP (1:2000)
were used for developing the membrane. The SDS gels were
scanned by CanonPI CS-U 3.8.1×scanner and the western blot was
developed and scanned on Alpha Innotech FluoChem Instrument.
The intensities of the bands were integrated and recorded using thef a predominantly α-helical fold B, (C) Thermal melt data from the ROC domain in the
f protein stability in the presence of GDP and GTP for wild type and R1441C ROC domain.
Table 1
Tm values for ROC+/-R1441C and GDP/GTP.
Wild type R1441C
GDP 52.5±0.8 47.8±0.3
GTP 50.4±0.2 46.6±0.4
GppNp 40.1±0.3 N/A
No ligand 37.7±0.1 N/A
Differences in stability due to presence of GDP or GTP for WT (Pb0.005) and R1441C
(Pb0.005) were signiﬁcant as assessed by Welch's t-test, with differences due to the
presence of mutation (i.e. WT vs. R1441C) in the case GDP (Pb0.0001) or GTP
(Pb0.000005) also being signiﬁcant.
Fig. 2. Pulldown analysis of the afﬁnity of wild type and R1441C ROC domain for each
other showing a signiﬁcant decrease in the ability of ROC domain containing the
R1441C mutation to precipitate the wild type domain. Analysis was carried out by two-
way ANOVA with variant and ligand as separate variables, using a Bonferronni post hoc
test. Indicated P values are ⁎⁎b0.01 and ⁎⁎⁎b0.001.
1196 Y. Li et al. / Biochimica et Biophysica Acta 1792 (2009) 1194–1197software Kodak Digital Science 1D 3.0.2 analysis package. Pulldowns
were replicated 3 times.
3. Results
To examine the secondary structure and folding properties of the
ROC domain, we used two approaches—circular dichroism spectro-
polarimetry and differential scanning ﬂuorimetry. CD analysis showed
that the ROC domain forms ordered secondary structure in solution,
with an absorbance spectrum suggestive of a predominantlyα-helical
fold with double minima at λ208 and 222 (Fig. 1A). This is in
agreement with data from the crystal structure of the ROC domain,
which revealed 46.5% α-helix and 21.6% β-pleated sheet, and with
molecular modeling studies based upon the small GTPases [21]. Using
graduated thermal melting, and following the percentage of folded
protein using absorbance at 220 nm with CD, the ROC domain was
found to unfold in a co-operative manner (Fig. 1B). The mid-point of
thermal denaturation or Tm determined by the loss of α-helical
structure was 41 °C for the ROC domain in water in the absence of
nucleotides. Using DSF to report the exposure of the hydrophobic core
in the absence of nucleotides, the ROC domain unfolded with a very
similar Tm of 39 °C (Fig. 1C). As previously demonstrated with H-Ras,
the presence of guanosine nucleotides has a major impact on the
stability of the LRRK2 ROC domain (Fig. 1D), increasing the Tm to
52.5 °C and 50.4 °C in the presence of GDP and GTP, respectively [22].
The R1441C mutation caused a destabilization of the ROC domain,
decreasing the Tm by 4° in the presence of GDP and 5.5° in the
presence of GTP as compared to the wild type domain (Fig. 1D and
Table 1).
Based upon previous work examining LRRK2 self-interaction using
LRRK2 and fragments expressed in mammalian cell culture [23], we
assessed ROC–ROC domain interactions between WT homodimers
and WT/R1441C heterodimers with puriﬁed protein in solution,
mimicking the situation in humans with heterozygous mutations.
Using ROC domains with different epitope tags (6xHistag and V5), a
signiﬁcant decrease was observed in the interaction between mutant
and WT domains (Fig. 2). The interaction between WT and R1441C
was lower still in the presence of GTP.
4. Discussion
We have previously shown that the R1441Cmutation in the LRRK2
ROC domain results in a decrease in GTPase activity. Based on the
model of a dimeric ROC–ROC structure, we predicted that themutated
residue sits at the interface in a dimeric structure for the ROC domain.
In the current study, we sought to test the hypothesis that the R1441C
mutation decreases the thermodynamic stability of the ROC domain
and to investigate the impact of guanosine nucleotides on the folding,
stability and self-interaction of the ROC domain.
We assessed how the R1441C mutation and binding of guanosine
nucleotides inﬂuence the folding properties of the ROC domain in
solution. Using CD to assess secondary structure, we found that the
ROC domain of LRRK2 forms a predominantly α-helical secondary
structure in solution, agreeing with data from crystallographicstudies. Although of low resolution and describing only secondary
structure, this is the ﬁrst report of any structural information for
LRRK2 in solution. Using molecular ellipticity as a marker for percent
folded protein in solution, we carried out thermal denaturation of the
ROC domain, yielding a calculated Tm of 39 °C. Using DSF to measure
unfolded protein, we examined the impact of ligand binding and the
R1441C mutation on the stability of the ROC domain. As previously
shownwith single domain GTPases, MgCl2 and guanosine nucleotides
substantially increase the stability of the ROC domain, with GDP
having a more pronounced impact than GTP [22]. This suggests,
indirectly, an alteration in the three-dimensional structural organi-
zation of the domain between the GDP and GTP bound states, and
supports the thesis that the ROC domain is acting as a molecular
switch [9]. This ﬁnding requires further investigation using high-
resolution structural approaches. Intriguingly, the R1441C mutation
consistently and signiﬁcantly lowered the stability of the ROC in the
presence of either GTP or GDP, suggesting that this mutation acts to
destabilize the ROC domain. These data suggest that R1441 plays an
important role in the structural integrity of the GTPase domain itself,
which is consistent with the crystal structural data of LRRK2 ROC
dimer [21]. Due to the fact that the R1441 residue is not conserved
between the ROCO proteins and the small GTPases such as a Ras and
Rho, it is not possible to study or compare the impact of alterations at
this residue in these proteins. We went on to examine ROC domain
self-interaction in the light of data showing the impact of GDP and
GTP on the stability of the ROC domain using differentially tagged ROC
domain constructs. Results from these experiments demonstrate that
the strength of interaction between differentially tagged ROC domain
monomers is altered in the presence of GDP or GTP, that these have
1197Y. Li et al. / Biochimica et Biophysica Acta 1792 (2009) 1194–1197additive effects on stability of the ROC domain in the presence of the
R1441C mutation. These data are consistent with structural informa-
tion indicating that the R1441C mutation is distal from the GTP
binding site and suggests that there are separate effects of guanine
nucleotides and the R1441C mutation. These results also support
previous data from our group looking at the interaction between full
length LRRK2 frommammalian cell lysates and the ROC domain in the
presence and absence of the mutation [21]. Both the stability data and
the pulldown data suggest that there is an alteration in the three-
dimensional structure of the ROC domain based upon whether GDP or
GTP is bound in the active site, again consistent with studies carried
out on the small GTPases [24]. We are currently investigating this
further using a variety of techniques. It is important to note that these
studies need extending to larger, multi-domain fragments of LRRK2 in
order to shed light on the nature and location of the interactions
between the components of the LRRK2 dimer. To date, we have not
been able to purify fragments larger than the ROC domain that are
stable in solution, and so such further studies wait upon overcoming
this technical hurdle.
In summary, our investigations into the folding, stability and self-
interaction properties of the ROC domain suggests a potential
mechanism for dysfunction and loss of GTPase activity of the ROC
domain based upon a decrease in stability associated with the R1441C
mutation found in familial Parkinson's disease. They represent the
ﬁrst description of a folding analysis of any of the domains of LRRK2.
Future experiments dissecting the relationship between stability and
functionmay shed light on the underlying cause of LRRK2 dysfunction
linked to ROC domain mutations, and it will be important to extend
these studies using larger fragments of LRRK2 and other mutations.
These data also highlight the possibility of targeting the stability of the
LRRK2 ROC domain as a potential therapeutic avenue to correcting the
dysfunction of this domain, artiﬁcially reverting the destabilizing
impact of the R1441C mutation.
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